NuraLogix, a pioneer of contactless health monitoring through its patented Transdermal Optical Imaging (TOI) technology, has announced a new capability for assessing fatty liver disease. Using the NuraLogix platform, which measures vital signs and provides an overall health risk assessment, the company’s researchers have developed artificial intelligence (AI) models that predict a person's risk of having fatty liver disease (FLD) using facial blood patterns.
“Many people with this condition are unaware of it and drift further into metabolic complications,” said Dr Keith Thompson, chief medical officer at NuraLogix. “This research shows the potential of the platform to screen for FLD and help users intervene with necessary lifestyle changes to prevent a ‘waterfall’ event such as liver failure.”
The new capabilities add to the existing health and wellness measurements the Nuralogix Anura platform can assess from a 30-second video selfie, including blood pressure, cardiac workload, heart rate variable and respiratory rate. The platform uses a video camera to extract facial blood flow information, which is then combined with powerful AI models developed from more than 40,000 patients with multiple health conditions, and analysed in the cloud to obtain health information based on the pattern of facial blood flows.
Click here to read the original news story